RecoRNA

RECORNA (Guangzhou) Biotechnology Co., Ltd. is an innovative drug research and development company with independent intellectual property rights, based on RNA-targeted editing technology. Building on internationally advanced RNA editing technology, the company is committed to developing innovative drugs for conditions that pose a threat to human health and currently lack effective conventional treatments or DNA editing therapies. RecoRNA was co-founded by a team of scientists led by a Stanford University returnee doctor and pharmaceutical executives with management experience in both international and domestic pharmaceutical companies. It focuses on the research and development of disease treatments based on RNA editing technology to address unmet clinical needs worldwide and provide safer and more effective RNA editing drugs and targeted RNA treatment solutions. The company is actively engaged in drug development for rare genetic diseases, neurological disorders, chronic illnesses, and other therapeutic areas with unmet clinical needs.